Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
sts - imho if the offering is occurs and is less than 5 mil buy on the dip. Maybe it will just be the LOC, but if not it likely maybe an opportunity if the offering is small in relation to the o/s. FWIW jmho
LN as long as most bio have upcoming phases, or a PDUFA or Adcom etc within a few months, EPS dips are dips but the catalysts are where it is at, imho. Important to watch on many bios with a thin revenue stream is any cash needs to carry it through the catalyst and beyond, since many times an offering will raise hell with the SP.
NAVB Good news today- PH3 trial is closed and SNDA will follow in the fall, nice catalysts.
That coupled with the PH2 for Alzheimer's should all work as good catalysts. The EPS was a tad off today, but research companies are like that much of the time.
BOl to all the holders.
T2M
Whas smart play.
Very nice News today, we should gap up! jmho
CBMX rule of mine is not to chase and 13+% gain in one day violate so I will just be a spectator most likely. Kudos on getting some.
Excellent early calls on MCOX - doing a board search reveals Charlie, heber and CJ some of the earliest a few months ago. Worth the wait obviously. KUDOS to you guys
ZX <Link back> auto profit exit 17%-
RTN looks like that is why it is up 13.3% on good volume today. Oh well missed that one should have been in last week. BOL
RTN - CBMX What is the catalyst?
TIA
CJ ya gotta be careful of what you chase, you could catch up with it, and if it turns around you could be lunch.
Good luck with the Hippos, Rhinos, Elephants, Lions and Giraffes, and watch out for the black mamba. Keep issuing stock tips from the safety of your tent, and the sanctuary of your mosquito netting. Have fun. PS are lions deterred by canvas?
AUXL<link back 3x annotated chart> This one is trading well and holding its own to start a leg, based on today's EPS statement. I bought in more today selectively since imo it will move up from this 19-20 level fairly quickly now, imo within the next week+. jmho
BSTC- Bob imo you are correct it should help both. Currently BSTC's visibility is less, but when the retail wakes up (should be soon now due to AUXLs earnings report- it has nice potential gains based on the shared PDUFA with AUXL.
AUXL <link back 2x for annotated chart> It had a nice start to the leg up this morning. Flipped and then re-bought within a 1/2 hr- some very nice start going into a PDUFA as Sheff just mentioned.
AUXL News Today EPS surprise
It should start moving more now and break out of range bound as of today. jmho
Here's is why:
7:18AM Auxilium Pharma beats by $0.14, beats on revs; guides FY13 revs in-line (AUXL) : Reports Q2 (Jun) earnings of $0.22 per share, excluding non-recurring items, $0.14 better than the Capital IQ Consensus Estimate of $0.08; revenues rose 28.5% year/year to $100.5 mln vs the $90.59 mln consensus. Co issues in-line guidance for FY13, sees FY13 revs of $363-405 mln vs. $371.84 mln Capital IQ Consensus Estimate, prior range $360-415 mln.
AUXL NEWS EPS++ - <link back annotated chart from last week> News Today EPS surprise
It should start moving more now and break out of range bound as of today. jmho
Here's is why:
7:18AM Auxilium Pharma beats by $0.14, beats on revs; guides FY13 revs in-line (AUXL) : Reports Q2 (Jun) earnings of $0.22 per share, excluding non-recurring items, $0.14 better than the Capital IQ Consensus Estimate of $0.08; revenues rose 28.5% year/year to $100.5 mln vs the $90.59 mln consensus. Co issues in-line guidance for FY13, sees FY13 revs of $363-405 mln vs. $371.84 mln Capital IQ Consensus Estimate, prior range $360-415 mln.
AUXL <link back annotated chart from last week> News Today EPS surprise
It should start moving more now and break out of range bound as of today. jmho
Here's is why:
7:18AM Auxilium Pharma beats by $0.14, beats on revs; guides FY13 revs in-line (AUXL) : Reports Q2 (Jun) earnings of $0.22 per share, excluding non-recurring items, $0.14 better than the Capital IQ Consensus Estimate of $0.08; revenues rose 28.5% year/year to $100.5 mln vs the $90.59 mln consensus. Co issues in-line guidance for FY13, sees FY13 revs of $363-405 mln vs. $371.84 mln Capital IQ Consensus Estimate, prior range $360-415 mln.
Smitter that is nice fundamental generater for sure.
Smitter yes almost forgot NBRI - that has done very well for us.
NHYT is running organically quite well, taking its time ratcheting along north.
Big GRPR KUDOS - man that is moving just like you said it would!!!! Great heads up on both for all who invested.
Mark AMRN should do well over the near term future imo. I am just holding and watching. lol
HOVA the close today and the volume vs the 20MA vol should give us a better indication today, intraday is a tough call for anyone imo. If folks wish to use intraday then use the intraday chart with pivot pts and watch the P base line violation south and the S-1, S-2 usually if one goes they both do, and it is a southern day or violation north of base up through R1 to R-2+ usually means a northern day. jmho That is what I use anyway on Schwab
GTXI - Doing some gap filling today, imo due to profit taking by people who flipped in 4.4 and out at 5.
With an ATR of .42 on the chart looks like it is fine so far with the small dip.
If we climb again with volume at *close, imo many will then start jumping in. jmho
As usual time will tell.
BOL
GTXI Sam <link back> this one is acting very much as indicated by that chart
Hi Sam - ref BIOD I still have a bunch and the chart looks like it is going to move north more.
Today has been a strong day and if we get decent volume tomorrow we should have a nice follow through for the leg. I am seeing the near future as a good possibility in the 5s and it has a catalyst on Sept.30th Ph2 so it well could pass that.
This one is a good trading stock with a nice pattern.
BOL - Sam
Hi softy, just hoping it didn't sell me out tooooooo early lol I am going to look for a consolidation since I think the chart is getting a bit toppy, either this week or next should pull back some imho but who knows?
How are you doing today?
T2M
PRAN<auto profit sell> 15% gain nice hold for a few days.
Cabos it is the old blind squirrel getting the occasional chart acorn. Thanks bud, I got more on that dip, hope others did as well
Sheff- the adcom is a catalyst. If they just start the 6month PDUFA clock after resubmission is accepted not sure where that ends up, Feb, Mar etc.
From your lips to God's ear on Feb.
T2M
CHTP a delay- PDUFA Clock now extended- Jan appears no longer a valid date, perhaps later in the spring of 2014? - http://finance.yahoo.com/marketupdate/inplay
7:32AM Chelsea Therapeutics announces update to NORTHERA (Droxidopa) NDA Filing; FDA identified certain technical deficiencies (CHTP) 3.07 : Co announced that the FDA, upon further review of the Company's resubmitted New Drug Application (NDA) for NORTHERA (droxidopa), has identified certain technical deficiencies in the resubmission that will require resolution prior to the resubmission being deemed a complete response. As previously announced on July 17, 2013, Chelsea had received written confirmation from the FDA that the resubmission was deemed to be a complete response to its March 28, 2012 Complete Response Letter and was assigned a new PDUFA date of January 3, 2014. However, the FDA has now notified the Company that they have noted deficiencies that relate primarily to the formatting of certain submitted electronic datasets and statistical programs describing the methods used to generate tables and listings. The deficiencies are unrelated to study conduct, interpretability of study results, or validity of study conclusions. The Company believes that the matter can be resolved quickly, and expects to submit the necessary response in August. Until the response is received by FDA, the Agency has informed Chelsea that the six month review clock for the NDA specified under the Prescription Drug User Fee Act (PDUFA) will not start. Therefore, upon a successful resubmission with the currently requested changes sought by the FDA, a new PDUFA date will be set by the Agency.
Softy I agee and if it is bottoming as I suspect it should move back before long. jmho